GlobeNewswire Inc | Sep 14, 2020 10:06AM EDT

September 14, 2020

WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Professor Eitan Kerem, M.D.has joined the Company as a Senior Consultant. Dr. Keremwillcontinueto adviseon our cystic fibrosis program focusing on strategic leadership, cystic fibrosis medical safety review, and medical communications, as well as liaising with patient advocacy groups and regulatory authorities.

Wearevery pleased to welcome to Eloxx someone of Dr.Kerems caliber and recognized expertise in cystic fibrosis as we advance our Phase 2 proof of concept clinical trial program for ELX-02in patients with nonsense mediated cystic fibrosis, for whom a high unmet medical need exists, said Dr. Gregory Williams, Chief Executive Officer of Eloxx Pharmaceuticals. We believe that Dr. Kerems vast experience in cystic fibrosis will provide us with critical counsel as we approach a substantial value inflection point for our Company. It is our highest priority to report top line results from our Phase 2 clinical trial program as soon as feasible.

Dr. Kerem joined Eloxx on September 1st upon his retirement from Hadassah Medical Centerwhere he most recently served as Head of Pediatrics and Professor of Pediatrics at Hebrew University Hadassah Medical School. Dr. Kerem was a board member of the European Cystic Fibrosis Society where he contributed to the development of the European Cystic Fibrosis Registry and was the President of CIPP, the Annual International Congress on Pediatric Pulmonology. Dr. Kerem was previously a member of the editorial boards of the leading journals in the field of pulmonology, Pediatric Pulmonology, "Chest" and the American Journal of Respiratory and Critical Care Medicine.

Dr. Keremhas been intimately involved with ELX-02 and the Eloxx team since 2015, originally working with Professor Timor Baasov at the Technion Institute to optimize ELX-02 in the early stages of its development. He is a globallyrenownedcystic fibrosis Key Opinion Leader and hashelped guideEloxx through the development of our clinical trial program. Dr. Kerem serveson our Cystic Fibrosis Medical Advisory Board, has been the Global Lead Investigator for our Phase 2 cystic fibrosis clinical trial program and had served as Chairman of the Safety Review Committee.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-throughtherapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxxs lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxxs preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ. For more information, please visit www.eloxxpharma.com.

Forward-LookingStatements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors,including: the development of the Companys read-through technology; the approval of the Companys patent applications; the Companys ability to successfully defend its intellectual property or obtain necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Companys research and development programs and collaborations; the Companys ability to obtain applicable regulatory approvals for its current and future product candidates; the acceptance by the market of the Companys products should they receive regulatory approval; the timing and success of the Companys preliminary studies, preclinical research, clinical trials, and related regulatory filings; the ability of the Company to consummate additional financings as needed; the impact of global health concerns, such as the COVID-19 global pandemic, on our ability to continue our clinical and preclinical programs and otherwise operate our business effectively; as well as those discussed in more detail in our Annual Report on Form 10-K and our other reports filed with theSecurities and Exchange Commission.

Contact:

Barbara Ryan 203-274-2825

barbarar@eloxxpharma.com

SOURCE: Eloxx Pharmaceuticals, Inc.